Clik here to view.
BioDelivery on track for mid-year NDA filing
BioDelivery Sciences (NASDAQ:BDSI) is on track to file a new drug application with the FDA this summer for its Bunavail treatment for opioid dependence, one of two Phase 3 candidates in its product...
View ArticleClik here to view.
Highline starts Titan Pharma at buy
Highline Research Advisors has launched coverage of Titan Pharmaceuticals (OTC:TTNP) with a “buy” rating and $3 price target. Shares of Titan were changing hands at 79.5 cents in the afternoon session...
View ArticleClik here to view.
Titan implanting treatments for opioid dependence
In the continuing struggle to circumvent abuse of drugs to treat opioid dependence and enhance compliance regimes for better outcomes, Titan Pharmaceuticals (OTCBB:TTNP) is leading the race with a...
View ArticleClik here to view.
Roth starts Titan Pharma at buy
Roth Capital Partners has launched coverage of Titan Pharmaceuticals (OTCBB:TTNP) with a “buy” rating and a price target of $1.25. The stock closed at 47 cents on Monday. “The impetus for our buy...
View ArticleClik here to view.
Relmada cleared for PK study with BuTab
Relmada Therapeutics (OTCQB:RLMD) has received a No Objection Letter from Health Canada to conduct the first pharmacokinetic study with novel formulations of oral, enteric-coated buprenorphine (BuTab,...
View ArticleClik here to view.
BioDelivery posts disappointing Clonidine trial results
Shares of BioDelivery Sciences International (NASDAQ:BDSI) lost more than a quarter of their market value at the mid-session on Monday after the company announced disappointing Phase 3 trial results...
View ArticleClik here to view.
Relmada begins proof-of-concept trial for BuTab
Relmada Therapeutics (OTCQB:RLMD) has commenced a proof-of-concept pharmacokinetic study with its novel formulations of oral, enteric-coated buprenorphine (BuTab, or REL-1028) being developed for both...
View ArticleClik here to view.
Titan Pharma posts positive Phase 3 Probuphine results
Titan Pharmaceuticals (OTCQB:TTNP) has reported positive topline results from a Phase 3 double blind, double dummy clinical study of Probuphine, its subdermal implant containing buprenorphine HCl for...
View ArticleClik here to view.
Titan Pharma Phase 3 data validate ProNeura technology
Titan Pharmaceuticals’ (OTCQB:TTNP) positive topline results from a Phase 3 clinical study of Probuphine, its subdermal implant of buprenorphine for the long-term maintenance treatment of opioid...
View ArticleClik here to view.
Braeburn resubmits NDA for Titan Pharma’s Probuphine
Titan Pharmaceuticals (OTCQB: TTNP) said its development partner, Braeburn Pharmaceuticals, has resubmitted an NDA to the FDA for Probuphine, Titan’s subdermal implant containing buprenorphine HCl for...
View ArticleClik here to view.
Braeburn Pharma commends HHS plan on opioid addition
Closely-held Braeburn Pharmaceuticals has commended U.S. Department of Health and Human Services (HHS) Secretary Sylvia Burwell on her announcement that HHS will expand access to medication-assisted...
View ArticleClik here to view.
FDA accepts Probuphine NDA resubmission; Titan prepares for NASDAQ uplisting
The FDA has accepted for review an NDA for Titan Pharmaceuticals’ (OTCQB:TTNP) Probuphine, a six-month subdermal implant containing buprenorphine hydrochloride for the long-term maintenance treatment...
View ArticleClik here to view.
Titan Pharma advancing pipeline in PD, other disorders
Titan Pharmaceuticals (NASDAQ:TTNP), which is awaiting an FDA approval decision for its six-month Probuphine implant to treat opioid dependence, is advancing its ProNeura implant technology against...
View ArticleClik here to view.
Obama to expand MAT in opioid addiction
President Barack Obama has tackled the opioid epidemic this week by telling health care providers across the country that access to medication-assisted treatment (MAT) must be expanded. He released an...
View ArticleClik here to view.
Opioid addiction treatment continues to grab headlines
An article in the latest issue of Guernica, a magazine of art and politics, details the plight of doctors prescribing buprenorphine, a medication for the treatment of opiate addiction. Unlike...
View ArticleClik here to view.
Titan Pharma’s Probuphine featured on CNBC
CNBC has highlighted Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant of buprenorphine in a feature about the treatment of opioid addiction and the crisis of fatal overdoses in the...
View ArticleClik here to view.
FDA approves Titan’s Probuphine implant for opioid dependence
The FDA has approved Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant, the first product for the long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or...
View ArticleClik here to view.
Roth ups Titan Pharma price target to $10
Roth Capital Partners has raised its price target for Titan Pharmaceuticals (NASDAQ:TTNP) to $10 from $7.75 after the FDA approved Titan’s six-month Probuphine implant for the treatment of opioid...
View ArticleClik here to view.
Titan Pharma receives milestone on Probuphine approval
Titan Pharmaceuticals (NASDAQ:TTNP) has received a $15-million milestone payment from development and commercialization partner, Braeburn Pharmaceuticals, following FDA approval of Probuphine, the...
View ArticleClik here to view.
First patients treated with Titan Pharma’s Probuphine
The first 10 patients received treatment last week with Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine, following FDA approval on May 26. Probuphine was developed using...
View Article
